Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat ...

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with ...

By disparaging public-health methods and discrediting vaccines, the COVID‑19 minimizers cost hundreds of thousands of people ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...